arrow
返回

High Concentrations of Polyelectrolyte Complex Nanoparticles Decrease Activity of Osteoclasts

delete2019-06-25
delete5
delete
OA
AI
V
Vivien Kauschke
F
Felix Maximilian Hessland
M
Martin Müller
C
Christian Heiß
K
Katrin Susanne Lips *
DOI:10.3390/molecules24122346delete
delete原文链接
delete分享
delete收藏
查看原文
摘要

摘要

En 中文
Fracture treatment in osteoporotic patients is still challenging. Osteoporosis emerges when there is an imbalance between bone formation and resorption in favor of resorption by osteoclasts. Thus, new implant materials for osteoporotic fracture treatment should promote bone formation and reduce bone resorption. Nanoparticles can serve as drug delivery systems for growth factors like Brain-Derived Neurotrophic Factor (BDNF), which stimulated osteoblast differentiation. Therefore, polyelectrolyte complex nanoparticles (PEC-NPs) consisting of poly(l-lysine) (PLL) and cellulose sulfate (CS), with or without addition of BDNF, were used to analyze their effect on osteoclasts in vitro. Live cell images showed that osteoclast numbers decreased after application of high PLL/CS PEC-NPs concentrations independent of whether BDNF was added or not. Real-time RT-PCR revealed that relative mRNA expression of cathepsin K and calcitonin receptor significantly declined after incubation of osteoclasts with high concentrations of PLL/CS PEC-NPs. Furthermore, Enzyme-Linked Immunosorbent Assay indicated that tartrate-resistant acidic phosphatase 5b activity was significantly reduced in the presence of high PLL/CS PEC-NPs concentrations. Consistent with these results, the pit formation analysis showed that less hydroxyapatite was resorbed by osteoclasts after incubation with high concentrations of PLL/CS PEC-NPs. BDNF had no influence on osteoclasts. We conclude that highly concentrated PLL/CS PEC-NPs dosages decreased osteoclastogenesis and osteoclasts activity. Moreover, BDNF might be a promising growth factor for osteoporotic fracture treatment since it did not increase osteoclast activity.
Keyword:
osteoclasts
polyelectrolyte complex nanoparticles
BDNF
drug delivery system
cathepsin K
calcitonin receptor
tartrate-resistant acidic phosphatase 5b
pit formation
AI总结

AI总结

对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。

期刊

Molecules 封面图
Molecules
IF:
4.6
论文数:
6.5W
被引数:
27.3W

机构

J
Justus Liebig University Giessen
学者数:
242
论文数: 81
被引数: 2
L
Leibniz Institut für Polymerforschung Dresden
学者数:
9
论文数: 5
被引数: 3
引用论文

引用论文

Synthesis and characterization of model urethane compounds
err2002-05-01
err0
PREAI
errZ. Y. Qin; C. W. Macosko; Stephen T. Wellinghoff
err分享
err收藏
The all-pay auction with complete information
err1996-06-01
err0
errOAAI
errMichael R. Baye; Dan Kovenock; Casper G. de Vries
err分享
err收藏
VDACs Post-Translational Modifications Discovery by Mass Spectrometry: Impact on Their Hub Function
err2021-11-27
err0
errOAAI
errMaria Gaetana Giovanna Pittalà; Stefano Conti Nibali; Simona Reina; Vincenzo Cunsolo; Antonella Di Francesco; Vito De Pinto; Angela Messina; Salvatore Foti; Rosaria Saletti
err分享
err收藏
Apomixis--The Asexual Revolution
err1996-11-22
err0
PREAI
errJean-Philippe Vielle Calzada; Charles F. Crane; David M. Stelly
err分享
err收藏
An Optimized Method to Generate Human Active Osteoclasts From Peripheral Blood Monocytes
err2018-04-04
err32
errOAAI
errAbdallah, Dina; Jourdain, Marie-Laure; Braux, Julien; Guillaume, Christine; Gangloff, Sophie C.; Jacquot, Jacky; Velard, Frederic
err分享
err收藏
Gene and protein expression of brain-derived neurotrophic factor and TrkB in bone and cartilage
errBONE
IF3.6
err2001-04-01
err60
PREAI
errYamashiro, T; Fukunaga, T; Yamashita, K; Kobashi, N; Takano-Yamamoto, T
err分享
err收藏
Pro-osteoclastic in vitro effect of Polyethylene-like nanoparticles: Involvement in the pathogenesis of implant aseptic loosening
err2016-06-14
err9
errOAAI
errBrulefert, Kevin; Cordova, Luis A.; Brulin, Benedicte; Faucon, Adrien; Hulin, Philipe; Nedellec, Steven; Gouin, Francois; Passuti, Norbert; Ishow, Elena; Heymann, Dominique
err分享
err收藏
A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: The oral calcitonin in postmenopausal osteoporosis (ORACAL) trial
err2012-03-21
err125
errOAAI
errBinkley, Neil; Bolognese, Michael; Sidorowicz-Bialynicka, Anna; Vally, Tasneem; Trout, Richard; Miller, Colin; Buben, Christine E.; Gilligan, James P.; Krause, David S.
err分享
err收藏
学者 查看更多内容